ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2017
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 266 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
266 citing papers in PubMed, 1 synthesis or guideline pooled it.
- APOE ε4-associated hippocampal atrophy trajectories across the Alzheimer's disease continuum: a systematic review, meta-analysis, and longitudinal validation.Frontiers in aging neuroscience · 2026Pooled it
- Eight-week multi-domain cognitive training does not impact large-scale resting-state brain networks in Parkinson's disease.NeuroImage. Clinical · 2022Trial
- Proteomic dysregulation associated with cerebral amyloid angiopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The dual diversity crisis in alzheimer's disease research: why neuroimaging biomarkers and clinical trials keep failing.GeroScience · 2026Article
- White Matter Slow-4 fALFF as a Complementary Marker in the Multimodal Alzheimer's Disease Biomarker Landscape.bioRxiv : the preprint server for biology · 2026Article
- Improving racial fairness in brain age models using style-transfer synthesis.bioRxiv : the preprint server for biology · 2026Article
- Separating ECog scale-score information from dyad availability: observation-process contributions to dyadic prediction of cognitive impairment in ADNI.Research square · 2026Article
- Are the factors associated with cognitive performance generalizable across cohorts?NeuroImage. Clinical · 2026Article
- Interpretable multimodal MRI fusion in Alzheimer's disease classification using extended parallel multilink joint ICA and 3D ResNet.iScience · 2026Article
- Gender bias in the diagnosis of Alzheimer's Disease.Research square · 2026Article
- Identification of MRI-Derived Structural Biomarkers in Female Alzheimer's Disease Subjects Using CAT12 and Mimics: Effects of Voxel Geometry on Biomarker Estimation.Life (Basel, Switzerland) · 2026Article
- The Substrate-Engine Model of Ferroptosis: Stage-Specific Targeting of Acyl-CoA Synthetase Long-Chain Family Member 4 and 5‑Lipoxygenase in Alzheimer's Disease.ACS pharmacology & translational science · 2026Review
- The Associations of cerebral blood flow and white matter hyperintensities with tau and amyloid-beta across the Alzheimer's disease spectrum.Brain imaging and behavior · 2026Article
- Hyperoxic cerebral vasoconstriction in healthy humans: global, lobe, and regions of interest.Journal of applied physiology (Bethesda, Md. : 1985) · 2026Article
- Classification of tau status with machine learning models in amyloid-positive cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Normalization method for relative cerebral blood flow influences sex and cognitive status effects in nondemented older adults.Brain imaging and behavior · 2026Article
- Semi-quantitative tau PET approaches for Braak staging: concordance of CenTauRz and STOC with visual assessment.Annals of nuclear medicine · 2026Article
- FLAME: Federated Learning and Aggregated Multi-Model Ensemble for Multi-Class Alzheimer's Disease Stage Classification from Structured Clinical Data.Diagnostics (Basel, Switzerland) · 2026Article
- Neuropsychological criteria for Mild Cognitive Impairment (MCI) best identify neuroimaging-based risk profiles: A Department of Defense/Alzheimer's Disease Neuroimaging Initiative study.Journal of the International Neuropsychological Society : JINS · 2026Article
- MRecover: A Conditional Generative Model for Recovering Motion- Corrupted MR images Using AI Generated Contrast.Research square · 2026Article
206 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
introductionThe overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study.
methodsADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition.
resultsMultimodal analyses will provide insight into AD pathophysiology and disease progression. DISCUSSION: ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.